Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
Inhibrx Biosciences Inc INBX
$104.83
▲ +3.07%
(+$3.12)
🔥 High Short Interest
🎈 Low Float
🎢 High Beta
Open
$105.31
Prev Close
$101.71
Day Range
$102.51 – $107.90
52W Range
$28.16 – $155.29
Market Cap
$1.54B
Beta
3.16
EPS (TTM)
$-8.88
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-05-28 |
| Shares Out. | 14,670,000 |
| Website | inhibrx.com/ ↗ |
| Phone | 18587954220 |
| Employees | 110 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$36.7M |
| Free Cash Flow | -$131.9M |
| Total Assets | $154.2M |
| Total Liabilities | $207.2M |
| Equity | -$53.0M |
About Inhibrx Biosciences Inc
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Inhibrx Biosciences Inc is a publicly traded company under the ticker symbol INBX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)